{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T15:49:26Z","timestamp":1787068166936,"version":"build-2736575974"},"reference-count":32,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100002383","name":"King Saud University","doi-asserted-by":"publisher","award":["RSP2024R74"],"award-info":[{"award-number":["RSP2024R74"]}],"id":[{"id":"10.13039\/501100002383","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","jiac-j.com","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Infection and Chemotherapy"],"published-print":{"date-parts":[[2024,10]]},"DOI":"10.1016\/j.jiac.2024.03.015","type":"journal-article","created":{"date-parts":[[2024,3,25]],"date-time":"2024-03-25T13:20:12Z","timestamp":1711372812000},"page":"1008-1014","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"title":["Novel \u03b2-lactam-\u03b2-lactamase inhibitors as monotherapy versus combination for the treatment of drug-resistant Pseudomonas aeruginosa infections: A multicenter cohort study"],"prefix":"10.1016","volume":"30","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1508-8693","authenticated-orcid":false,"given":"Thamer A.","family":"Almangour","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8850-1384","authenticated-orcid":false,"given":"Leen","family":"Ghonem","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dareen","family":"Alassiri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alanoud","family":"Aljurbua","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3861-9725","authenticated-orcid":false,"given":"Mohammed","family":"Al Musawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-5785-6382","authenticated-orcid":false,"given":"Aminah","family":"Alharbi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara","family":"Almuhisen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeelan","family":"Alghaith","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nader","family":"Damfu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Doaa","family":"Aljefri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wafa","family":"Alfahad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8504-3779","authenticated-orcid":false,"given":"Marwan","family":"Alrasheed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yaqoub","family":"Khormi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4920-3741","authenticated-orcid":false,"given":"Abdullah","family":"Almohaizeie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"9","key":"10.1016\/j.jiac.2024.03.015_bib1","doi-asserted-by":"crossref","first-page":"952","DOI":"10.1002\/phar.2449","article-title":"Approach to the treatment of patients with Serious multidrug-resistant Pseudomonas aeruginosa infections","volume":"40","author":"O'Donnell","year":"2020","journal-title":"Pharmacotherapy"},{"issue":"Suppl 1","key":"10.1016\/j.jiac.2024.03.015_bib2","article-title":"Geographic and temporal patterns of antimicrobial resistance in Pseudomonas aeruginosa over 20 Years from the SENTRY antimicrobial surveillance Program, 1997-2016","volume":"6","author":"Shortridge","year":"2019","journal-title":"Open Forum Infect Dis"},{"issue":"1","key":"10.1016\/j.jiac.2024.03.015_bib4","doi-asserted-by":"crossref","DOI":"10.4081\/gh.2020.868","article-title":"Employment of mapping technology in antimicrobial resistance reporting in Saudi Arabia","volume":"15","author":"Alhifany","year":"2020","journal-title":"Geospatial Health"},{"issue":"4","key":"10.1016\/j.jiac.2024.03.015_bib5","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijantimicag.2020.106104","article-title":"Management of infections caused by WHO critical priority Gram-negative pathogens in Arab countries of the Middle East: a consensus paper","volume":"56","author":"Al Salman","year":"2020","journal-title":"Int J Antimicrob Agents"},{"issue":"12","key":"10.1016\/j.jiac.2024.03.015_bib6","doi-asserted-by":"crossref","first-page":"e379","DOI":"10.1016\/S1473-3099(18)30414-6","article-title":"Epidemiology of common resistant bacterial pathogens in the countries of the Arab League","volume":"18","author":"Moghnieh","year":"2018","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.jiac.2024.03.015_bib9","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.ijid.2017.06.007","article-title":"Comparison of antimicrobial activity between ceftolozane-tazobactam and ceftazidime-avibactam against multidrug-resistant isolates of Escherichia coli, Klebsiella pneumoniae, and Pseudomonas aeruginosa","volume":"62","author":"Alatoom","year":"2017","journal-title":"Int J Infect Dis : IJID Offic Pub Int Soci Infectious Diseases"},{"issue":"4","key":"10.1016\/j.jiac.2024.03.015_bib10","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1016\/j.jiph.2022.02.009","article-title":"In-vitro activity of ceftolozane\/tazobactam against recent clinical bacterial isolates from two Saudi Arabian hospitals","volume":"15","author":"Bahabri","year":"2022","journal-title":"J Infection Pub Health"},{"issue":"2","key":"10.1016\/j.jiac.2024.03.015_bib11","doi-asserted-by":"crossref","DOI":"10.1093\/jacamr\/dlab067","article-title":"In vitro activity of ceftazidime\/avibactam against clinical isolates of Enterobacterales and Pseudomonas aeruginosa from Middle Eastern and African countries: ATLAS global surveillance programme 2015-18","volume":"3","author":"Karlowsky","year":"2021","journal-title":"JAC-Antimicrob Resistan"},{"issue":"3","key":"10.1016\/j.jiac.2024.03.015_bib12","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1089\/mdr.2020.0217","article-title":"Antimicrobial activity of ceftazidime-avibactam, ceftolozane-tazobactam and comparators tested against Pseudomonas aeruginosa and Klebsiella pneumoniae isolates from United States medical centers in 2016-2018","volume":"27","author":"Sader","year":"2021","journal-title":"Microb Drug Resist"},{"issue":"12","key":"10.1016\/j.jiac.2024.03.015_bib13","doi-asserted-by":"crossref","first-page":"3497","DOI":"10.1093\/jac\/dkz379","article-title":"Evaluation of in vitro activity of ceftazidime\/avibactam and ceftolozane\/tazobactam against MDR Pseudomonas aeruginosa isolates from Qatar","volume":"74","author":"Sid","year":"2019","journal-title":"J Antimicrob Chemother"},{"issue":"10","key":"10.1016\/j.jiac.2024.03.015_bib14","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.00875-17","article-title":"Multicenter evaluation of ceftazidime-avibactam and ceftolozane-tazobactam inhibitory activity against meropenem-nonsusceptible Pseudomonas aeruginosa from blood, respiratory tract, and wounds","volume":"61","author":"Grupper","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"issue":"12","key":"10.1016\/j.jiac.2024.03.015_bib15","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.01858-17","article-title":"Activity of ceftolozane-tazobactam and ceftazidime-avibactam against beta-lactam-resistant Pseudomonas aeruginosa isolates","volume":"61","author":"Humphries","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"issue":"11","key":"10.1016\/j.jiac.2024.03.015_bib16","doi-asserted-by":"crossref","first-page":"e4599","DOI":"10.1093\/cid\/ciaa1306","article-title":"Modifiable risk factors for the emergence of ceftolozane-tazobactam resistance","volume":"73","author":"Tamma","year":"2021","journal-title":"Clin Infect Dis : Offic Pub Infectious Diseases Soci Am"},{"issue":"2","key":"10.1016\/j.jiac.2024.03.015_bib17","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1093\/cid\/ciz816","article-title":"Ceftolozane\/tazobactam vs polymyxin or aminoglycoside-based regimens for the treatment of drug-resistant Pseudomonas aeruginosa","volume":"71","author":"Pogue","year":"2020","journal-title":"Clin Infect Dis : Offic Pub Infectious Diseases Soci Am"},{"issue":"9","key":"10.1016\/j.jiac.2024.03.015_bib18","doi-asserted-by":"crossref","first-page":"2519","DOI":"10.1093\/jac\/dky204","article-title":"Clinical activity of ceftazidime\/avibactam against MDR Enterobacteriaceae and Pseudomonas aeruginosa: pooled data from the ceftazidime\/avibactam Phase III clinical trial programme","volume":"73","author":"Stone","year":"2018","journal-title":"J Antimicrob Chemother"},{"issue":"3","key":"10.1016\/j.jiac.2024.03.015_bib19","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1128\/CMR.05041-11","article-title":"Combination therapy for treatment of infections with gram-negative bacteria","volume":"25","author":"Tamma","year":"2012","journal-title":"Clin Microbiol Rev"},{"issue":"5","key":"10.1016\/j.jiac.2024.03.015_bib20","doi-asserted-by":"crossref","first-page":"e61","DOI":"10.1093\/cid\/ciw353","article-title":"Management of adults with hospital-acquired and ventilator-associated pneumonia: 2016 clinical practice guidelines by the infectious diseases society of America and the American thoracic society","volume":"63","author":"Kalil","year":"2016","journal-title":"Clin Infect Dis : Offic Pub Infectious Diseases Soci Am"},{"key":"10.1016\/j.jiac.2024.03.015_bib21","doi-asserted-by":"crossref","DOI":"10.1093\/cid\/ciad428","article-title":"Infectious diseases society of America 2023 guidance on the treatment of antimicrobial resistant gram-negative infections","author":"Tamma","year":"2023","journal-title":"Clin Infect Dis : Offic Pub Infectious Diseases Soci Am"},{"issue":"8","key":"10.1016\/j.jiac.2024.03.015_bib22","doi-asserted-by":"crossref","DOI":"10.1128\/aac.00405-23","article-title":"Ceftolozane-tazobactam versus ceftazidime-avibactam for the treatment of infections caused by multidrug-resistant Pseudomonas aeruginosa: a multicenter cohort study","volume":"67","author":"Almangour","year":"2023","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jiac.2024.03.015_bib23","series-title":"Performance standards for antimicrobial susceptibility testing","first-page":"2018","year":"2018"},{"issue":"10","key":"10.1016\/j.jiac.2024.03.015_bib24","doi-asserted-by":"crossref","first-page":"818","DOI":"10.1097\/00003246-198510000-00009","article-title":"Apache II: a severity of disease classification system","volume":"13","author":"Knaus","year":"1985","journal-title":"Crit Care Med"},{"issue":"5","key":"10.1016\/j.jiac.2024.03.015_bib25","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1016\/0021-9681(87)90171-8","article-title":"A new method of classifying prognostic comorbidity in longitudinal studies: development and validation","volume":"40","author":"Charlson","year":"1987","journal-title":"J Chron Dis"},{"issue":"8","key":"10.1016\/j.jiac.2024.03.015_bib26","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1001\/jama.2016.0287","article-title":"The third international consensus definitions for sepsis and septic shock (Sepsis-3)","volume":"315","author":"Singer","year":"2016","journal-title":"JAMA"},{"issue":"3","key":"10.1016\/j.jiac.2024.03.015_bib27","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1111\/j.1469-0691.2011.03570.x","article-title":"Multidrug-resistant, extensively drug-resistant and pandrug-resistant bacteria: an international expert proposal for interim standard definitions for acquired resistance","volume":"18","author":"Magiorakos","year":"2012","journal-title":"Clin Microbiol Infection : Offic Pub Europ Soci Clinic Microb Infectious Diseases"},{"issue":"4","key":"10.1016\/j.jiac.2024.03.015_bib28","doi-asserted-by":"crossref","DOI":"10.1186\/cc2872","article-title":"Acute renal failure \u2013 definition, outcome measures, animal models, fluid therapy and information technology needs: the Second International Consensus Conference of the Acute Dialysis Quality Initiative (ADQI) Group","volume":"8","author":"Bellomo","year":"2004","journal-title":"Crit Care"},{"issue":"1","key":"10.1016\/j.jiac.2024.03.015_bib29","doi-asserted-by":"crossref","first-page":"55","DOI":"10.2165\/00002018-200932010-00005","article-title":"Drug-Induced Liver Injury Network (DILIN) prospective study: rationale, design and conduct","volume":"32","author":"Fontana","year":"2009","journal-title":"Drug Saf"},{"issue":"8","key":"10.1016\/j.jiac.2024.03.015_bib30","doi-asserted-by":"crossref","first-page":"1888","DOI":"10.1097\/01.CCM.0000275389.31974.22","article-title":"Optimal management therapy for Pseudomonas aeruginosa ventilator-associated pneumonia: an observational, multicenter study comparing monotherapy with combination antibiotic therapy","volume":"35","author":"Garnacho-Montero","year":"2007","journal-title":"Crit Care Med"},{"key":"10.1016\/j.jiac.2024.03.015_bib31","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1186\/1471-2334-12-308","article-title":"Impact of adequate empirical combination therapy on mortality from bacteremic Pseudomonas aeruginosa pneumonia","volume":"12","author":"Park","year":"2012","journal-title":"BMC Infect Dis"},{"issue":"12","key":"10.1016\/j.jiac.2024.03.015_bib32","doi-asserted-by":"crossref","first-page":"1803","DOI":"10.1093\/cid\/ciy378","article-title":"Difficult-to-Treat resistance in gram-negative bacteremia at 173 US hospitals: retrospective cohort analysis of prevalence, predictors, and outcome of resistance to all first-line agents","volume":"67","author":"Kadri","year":"2018","journal-title":"Clin Infect Dis : Offic Pub Infectious Diseases Soci Am"},{"issue":"1","key":"10.1016\/j.jiac.2024.03.015_bib33","article-title":"Ceftolozane-tazobactam combination therapy compared to ceftolozane-tazobactam monotherapy for the treatment of severe infections: a systematic review and meta-analysis","volume":"10","author":"Fiore","year":"2021","journal-title":"Antibiotics (Basel, Switzerland)"},{"issue":"6","key":"10.1016\/j.jiac.2024.03.015_bib34","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1016\/j.ijantimicag.2019.08.025","article-title":"Efficacy of ceftazidime\/avibactam in monotherapy or combination therapy against carbapenem-resistant Gram-negative bacteria: a meta-analysis","volume":"54","author":"Onorato","year":"2019","journal-title":"Int J Antimicrob Agents"},{"issue":"8","key":"10.1016\/j.jiac.2024.03.015_bib35","doi-asserted-by":"crossref","first-page":"2172","DOI":"10.1093\/jac\/dkab134","article-title":"Combination versus monotherapy as definitive treatment for Pseudomonas aeruginosa bacteraemia: a multicentre retrospective observational cohort study","volume":"76","author":"Babich","year":"2021","journal-title":"J Antimicrob Chemother"}],"container-title":["Journal of Infection and Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1341321X24000990?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1341321X24000990?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,11,14]],"date-time":"2024-11-14T19:20:02Z","timestamp":1731612002000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1341321X24000990"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10]]},"references-count":32,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2024,10]]}},"alternative-id":["S1341321X24000990"],"URL":"https:\/\/doi.org\/10.1016\/j.jiac.2024.03.015","relation":{},"ISSN":["1341-321X"],"issn-type":[{"value":"1341-321X","type":"print"}],"subject":[],"published":{"date-parts":[[2024,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Novel \u03b2-lactam-\u03b2-lactamase inhibitors as monotherapy versus combination for the treatment of drug-resistant Pseudomonas aeruginosa infections: A multicenter cohort study","name":"articletitle","label":"Article Title"},{"value":"Journal of Infection and Chemotherapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jiac.2024.03.015","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Japanese Society of Chemotherapy, Japanese Association for Infectious Diseases, and Japanese Society for Infection Prevention and Control. Published by Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}